KR101940014B1 - 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물 - Google Patents

신손상 및 신부전을 진단 및 예측하는 방법 및 조성물 Download PDF

Info

Publication number
KR101940014B1
KR101940014B1 KR1020127021086A KR20127021086A KR101940014B1 KR 101940014 B1 KR101940014 B1 KR 101940014B1 KR 1020127021086 A KR1020127021086 A KR 1020127021086A KR 20127021086 A KR20127021086 A KR 20127021086A KR 101940014 B1 KR101940014 B1 KR 101940014B1
Authority
KR
South Korea
Prior art keywords
delete delete
hours
subject
likelihood
serum creatinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127021086A
Other languages
English (en)
Korean (ko)
Other versions
KR20120123676A (ko
Inventor
조셉 앤더버그
제프 그레이
폴 맥퍼슨
케빈 나카무라
제임스 패트릭 캠프
Original Assignee
아스튜트 메디컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스튜트 메디컬 인코포레이티드 filed Critical 아스튜트 메디컬 인코포레이티드
Publication of KR20120123676A publication Critical patent/KR20120123676A/ko
Application granted granted Critical
Publication of KR101940014B1 publication Critical patent/KR101940014B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127021086A 2010-02-05 2011-02-04 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물 Active KR101940014B1 (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US30202710P 2010-02-05 2010-02-05
US30202110P 2010-02-05 2010-02-05
US30202610P 2010-02-05 2010-02-05
US30202510P 2010-02-05 2010-02-05
US30203610P 2010-02-05 2010-02-05
US61/302,021 2010-02-05
US61/302,025 2010-02-05
US61/302,026 2010-02-05
US61/302,036 2010-02-05
US61/302,027 2010-02-05
US37406010P 2010-08-16 2010-08-16
US61/374,060 2010-08-16
PCT/US2011/023830 WO2011097539A1 (en) 2010-02-05 2011-02-04 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
KR20120123676A KR20120123676A (ko) 2012-11-09
KR101940014B1 true KR101940014B1 (ko) 2019-01-21

Family

ID=44355818

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127021086A Active KR101940014B1 (ko) 2010-02-05 2011-02-04 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물

Country Status (23)

Country Link
US (2) US11454635B2 (https=)
EP (2) EP2531620B1 (https=)
JP (3) JP2013519095A (https=)
KR (1) KR101940014B1 (https=)
CN (2) CN102791885B (https=)
AU (1) AU2011213684B2 (https=)
BR (1) BR112012019542A2 (https=)
CA (1) CA2788826C (https=)
CY (1) CY1117784T1 (https=)
DK (1) DK2666872T3 (https=)
EA (1) EA201290629A1 (https=)
ES (1) ES2585184T3 (https=)
HK (1) HK1212764A1 (https=)
HR (1) HRP20160733T1 (https=)
HU (1) HUE029304T2 (https=)
MX (2) MX366653B (https=)
NZ (2) NZ700695A (https=)
PL (1) PL2666872T3 (https=)
PT (1) PT2666872T (https=)
RS (1) RS54879B1 (https=)
SI (1) SI2666872T1 (https=)
SM (1) SMT201600245B (https=)
WO (1) WO2011097539A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200057628A (ko) 2018-11-16 2020-05-26 서울대학교병원 비심장 수술 후 급성 신부전 발생 위험도 예측 시스템 및 방법
KR20230160511A (ko) 2022-05-17 2023-11-24 경북대학교 산학협력단 호중구 젤라티나제 리포칼린과 특이적으로 결합하는 펩타이드 및 이의 용도

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607703A (en) 2008-10-21 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
PT2666872T (pt) * 2010-02-05 2016-07-08 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2734494T3 (es) 2011-12-08 2019-12-10 Astute Medical Inc Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal
EP2834638B1 (en) * 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
TR201807542T4 (tr) 2013-01-17 2018-06-21 Astute Medical Inc Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.
WO2014120677A1 (en) * 2013-01-29 2014-08-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105556305A (zh) 2013-06-05 2016-05-04 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9822172B2 (en) 2013-11-06 2017-11-21 Astute Medical, Inc. Assays for IGFBP7 having improved performance in biological samples
US10300108B2 (en) 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN107003301B (zh) * 2014-10-20 2019-11-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6859334B2 (ja) 2015-10-08 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
JP7080176B2 (ja) 2016-02-29 2022-06-03 エフ．ホフマン－ラ ロシュ アーゲー 子癇前症におけるマーカーとしてのｉｇｆｂｐ－７
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
JP2020504157A (ja) 2017-01-12 2020-02-06 アスチュート メディカル，インコーポレイテッド Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11718682B2 (en) 2017-04-05 2023-08-08 Astute Medical, Inc. Assays for TIMP2 having improved performance in biological samples
CN112673259B (zh) 2018-07-20 2024-11-22 豪夫迈·罗氏有限公司 基于igfbp-7的先兆子痫预测
CN112635049A (zh) * 2020-12-23 2021-04-09 无锡市第二人民医院 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法
CN113892931B (zh) * 2021-10-14 2023-08-22 重庆大学 一种基于深度学习的fmcw雷达提取分析腹内压力方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065604A1 (en) 2004-12-13 2006-06-22 Renovar Incorporated Systems and methods for characterizing kidney disseases
WO2009036188A2 (en) 2007-09-11 2009-03-19 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (ru) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
CA1330302C (en) * 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
ES2258793T5 (es) 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU7549498A (en) 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6709855B1 (en) * 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
AU2055400A (en) * 1998-12-18 2000-07-03 Human Genome Sciences, Inc. Prostacyclin-stimulating factor-2
CA2356174A1 (en) 1998-12-21 2000-06-29 Monash University Kidney disease detection and treatment
US7071160B2 (en) 2000-06-15 2006-07-04 Kyowa Hakko Kogyo Co., Ltd. Insulin-like growth factor-binding protein
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
AU2002216273A1 (en) 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
JP2006508014A (ja) 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) * 2001-12-20 2002-02-06 Serono Internat S A Proteins
EP1481249A1 (en) 2002-03-07 2004-12-01 Cambridge University Technical Services Limited Scd fingerprints
WO2003081201A2 (en) 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
WO2004053074A2 (en) * 2002-12-06 2004-06-24 Science And Technology Corporation @ Unm Outcome prediction and risk classification in childhood leukemia
JP2006526140A (ja) * 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
CN1791797A (zh) 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
AU2004260083B2 (en) * 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US20070280930A1 (en) 2004-03-17 2007-12-06 Kasper Mathias Antoon Rouschop Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury
AU2005236075A1 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2006008661A2 (en) 2004-07-19 2006-01-26 Neurochem (International) Limited Diagnostic methods of multiple organ amyloidosis
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
EP1846576A4 (en) 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKERS OF TISSUE STATUS
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1877559B1 (en) 2005-04-18 2010-10-13 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2006272913B2 (en) 2005-07-21 2012-01-19 The Johns Hopkins University Methods of detecting and treating acute kidney injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
AU2006299417A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
CA2665489C (en) 2006-12-08 2017-08-29 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
CN106908603B (zh) * 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CN103399155A (zh) 2007-03-26 2013-11-20 诺瓦提斯公司 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签
EP2134866A2 (en) 2007-04-10 2009-12-23 Integragen Human diabetes susceptibility tnfrsf10b gene
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
WO2008150488A1 (en) 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
JP5661457B2 (ja) 2007-06-06 2015-01-28 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 腎疾患の予測診断
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
EP2203743A4 (en) 2007-09-20 2011-03-02 Univ Louisville Res Found PEPTIDE BIOMARKER FOR PREDICTING WEARNING OF THE KIDNEY FUNCTION AND A CHILDNESS
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
CN101896818B (zh) * 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
CA2716854A1 (en) 2008-02-29 2009-09-03 National University Corporation Nagoya University Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
US20090298106A1 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
WO2009143604A1 (en) * 2008-05-30 2009-12-03 University Of Alberta Molecular signature for fibrosis and atrophy
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US7998744B2 (en) 2008-07-28 2011-08-16 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
US8673574B2 (en) 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2735590A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
US9164097B2 (en) 2008-10-14 2015-10-20 National Research Council Of Canada Formulations targeting IGFBP7 for diagnosis and therapy of cancer
NZ607703A (en) 2008-10-21 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010048347A2 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102264230B (zh) 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2394166B1 (en) 2009-02-06 2016-07-13 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and failure
EP2427496A4 (en) 2009-04-03 2013-05-15 Vegenics Pty Ltd ANTI-VEGF-D ANTIBODIES
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US20110065599A1 (en) 2009-08-07 2011-03-17 Rules-Based Medicine, Inc. Methods and Devices for Detecting Kidney Damage
NZ598712A (en) 2009-08-28 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630277A (en) 2009-09-21 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
PT2666872T (pt) * 2010-02-05 2016-07-08 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
TR201807542T4 (tr) * 2013-01-17 2018-06-21 Astute Medical Inc Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249002A1 (en) 2002-05-14 2007-10-25 Renovar Incorporated Systems and methods for characterizing kidney diseases
WO2006065604A1 (en) 2004-12-13 2006-06-22 Renovar Incorporated Systems and methods for characterizing kidney disseases
WO2009036188A2 (en) 2007-09-11 2009-03-19 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin J Am Soc Nephrol., (2009.05), Vol. 4, pp 873-882.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200057628A (ko) 2018-11-16 2020-05-26 서울대학교병원 비심장 수술 후 급성 신부전 발생 위험도 예측 시스템 및 방법
KR20230160511A (ko) 2022-05-17 2023-11-24 경북대학교 산학협력단 호중구 젤라티나제 리포칼린과 특이적으로 결합하는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
US20230194552A1 (en) 2023-06-22
CA2788826C (en) 2023-09-26
EP2531620B1 (en) 2016-12-14
EP2666872B1 (en) 2016-04-27
US20130157881A1 (en) 2013-06-20
ES2585184T3 (es) 2016-10-04
CN105158481A (zh) 2015-12-16
HK1172658A1 (zh) 2013-04-26
JP2017078719A (ja) 2017-04-27
CA2788826A1 (en) 2011-08-11
SI2666872T1 (sl) 2016-08-31
PT2666872T (pt) 2016-07-08
NZ700695A (en) 2016-05-27
WO2011097539A1 (en) 2011-08-11
CY1117784T1 (el) 2017-05-17
EP2531620A1 (en) 2012-12-12
HRP20160733T1 (hr) 2016-07-15
NZ601590A (en) 2014-10-31
AU2011213684A1 (en) 2012-08-23
HK1212764A1 (zh) 2016-06-17
MX2012008956A (es) 2012-09-07
MX366653B (es) 2019-07-17
SMT201600245B (it) 2016-08-31
CN102791885B (zh) 2015-09-09
BR112012019542A2 (en) 2018-03-27
RS54879B1 (sr) 2016-10-31
JP2013519095A (ja) 2013-05-23
EA201290629A1 (ru) 2013-04-30
MX341191B (es) 2016-08-10
EP2531620A4 (en) 2013-07-31
JP6363154B2 (ja) 2018-07-25
AU2011213684B2 (en) 2014-11-20
KR20120123676A (ko) 2012-11-09
JP2018185320A (ja) 2018-11-22
US11454635B2 (en) 2022-09-27
HUE029304T2 (en) 2017-02-28
US12590975B2 (en) 2026-03-31
EP2666872A1 (en) 2013-11-27
PL2666872T3 (pl) 2016-10-31
CN102791885A (zh) 2012-11-21
DK2666872T3 (en) 2016-07-25

Similar Documents

Publication Publication Date Title
KR101940014B1 (ko) 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
KR102003258B1 (ko) 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
KR101760314B1 (ko) 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
AU2014207509B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP7217796B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
KR20110097850A (ko) 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
KR20110084286A (ko) 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
KR20140074307A (ko) 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물
HK1200218A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2016136154A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
KR20120061863A (ko) 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물
EP2585825B1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213685A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20160313350A1 (en) Methods for diagnosis and prognosis of renal injury and renal failure using trefoil factor 3 failure
WO2016077484A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2015508181A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6538353B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
ES2943579T3 (es) Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2880442A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140051099A (ko) 히알루론산을 이용하는 신장 손상의 평가를 위한 방법 및 조성물
HK1212774A1 (zh) 用於腎損傷和腎衰竭的診斷及預後方法和組合物
EP2951581A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1162617B (zh) 腎損傷和腎衰竭的診斷和預後
HK1167889B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1167888B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120810

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151230

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170519

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20180327

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190114

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211227

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221228

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241226

Start annual number: 7

End annual number: 7